Anti-IGLC2 antibody
Specifications
| Product Cat#: | AB-06-2369 |
| Product type: | Primary antibody |
| Antigen: | IGLC2 |
| Immunogen: | Recombinant protein |
| Species immunized: | Mouse |
| Isotype: | IgG1 |
| Applications: | Western Blot (1:500-1:1000); Immunohistochemistry (1:80-1:200) |
| Reactivity: | Human |
| Clonality (clone number): | Monoclonal (E12-B9) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Ig lambda chain C regions antibody |
| IGLC antibody | |
| Immunoglobulin lambda constant region 2 (Kern- Oz- marker) antibody | |
| MGC20392 antibody | |
| MGC45681 antibody | |
| Partial Ke Oz polypeptide antibody |
Target information
Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).
Provider
Erpantech Laboratory
